IDEXX's strategy to expand its global commercial capabilities is likely to enhance its CAG Diagnostics recurring revenue, which is a key growth area. This strategic move is expected to positively impact the stock price in the short term, as it shows the company's proactive approach to overcoming macroeconomic challenges.